Furthermore, a recent study on the same cell line and female C57BL/6 mice demonstrated that HSP at 125 mg/mL doses could inhibit melanogenic tumour growth by activating PI3K-Akt signalling and cytotoxic T lymphocyte and suppressed the tolerogenic T cell response [112]. The gene discussed is HSP90B2P; the disease is neoplasm.